Neurocrine Biosciences | Créances Commerciales



Trade Debtors Changement Date
AbbVie USD 10.92B 553M 2024-12
Acadia Pharmaceuticals USD 104.7M 5.67M 2024-12
Agios Pharmaceuticals USD 4.11M 991K 2024-12
ALKERMES USD 394.72M 24.54M 2024-12
Alnylam Pharmaceuticals USD 405.31M 51.46M 2024-12
Amgen USD 6.78B 535M 2024-12
Biogen USD 1.87B 119.3M 2024-12
BioMarin Pharmaceutical USD 660.54M 117.01M 2024-12
Cytokinetics USD 16.65M 16.41M 2024-12
Dynavax Technologies USD 46.91M 28.37M 2024-12
Exelixis USD 265.44M 4.27M 2025-01
Gilead Sciences USD 4.42B 167M 2024-12
Halozyme Therapeutics USD 308.46M 22.71M 2024-12
Incyte USD 853.15M 94.7M 2024-12
Intra Cellular Therapies USD 166.5M 20.89M 2024-12
Ionis Pharmaceuticals USD 92.19M 74.26M 2024-12
Neurocrine Biosciences USD 479.1M 2M 2024-12
Pfizer USD 14.78B 2.92B 2024-12
Prothena USD 0 0 2024-12
Regeneron Pharmaceuticals USD 6.21B 6B 2024-12
Repligen USD 129.03M 5.79M 2024-09
Sarepta Therapeutics USD 649.73M 133.74M 2024-12
Teva Pharmaceutical Industries USD 3.06B 403M 2024-12
Ultragenyx Pharmaceutical USD 123.6M 28.5M 2024-12
Vertex Pharmaceuticals USD 1.61B 141.2M 2024-12



Neurocrine Biosciences Créances Commerciales - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.